Gut Bacteria Molecule Linked to Increased Alzheimer's Risk and Cognitive Decline
A recent study shows that a gut bacteria molecule called ImP accelerates cognitive decline and increases Alzheimer's risk by promoting brain protein accumulation.
A new study reveals that a specific molecule produced by gut bacteria may increase the risk of Alzheimer's disease and accelerate cognitive decline in dementia patients. The discovery opens potential new avenues for preventive treatments.
From Gut to Brain
Published in the journal Nature Communications, the study focuses on ImP, or imidazole propionate, a metabolite produced by certain gut microbes. While these bacteria are not exceptionally common, their presence varies significantly among individuals, leading to vastly different blood concentrations of the molecule.
Researchers at the University of Wisconsin-Madison built upon decade-old research indicating differences in gut microbiomes between Alzheimer's patients and healthy individuals. In mouse experiments, the team discovered that when ImP enters the bloodstream and reaches the brain, it promotes the accumulation of amyloid-beta and tau proteins—hallmarks of Alzheimer's pathology that eventually damage and kill nerve cells.
Accelerated Cognitive Decline
Analyzing blood samples from approximately 1,200 participants in the Wisconsin Alzheimer's Disease Research Center registry, scientists found that individuals with higher ImP levels exhibited greater biomarkers for abnormal proteins and impaired neuronal function. Long-term cognitive evaluations further demonstrated that participants with elevated ImP levels experienced significantly faster cognitive deterioration.
"Because we have the results of the cognitive tests that these volunteers underwent over time, we can see that the people with the highest ImP levels also experienced much faster cognitive decline," said Professor Federico Ray.
Furthermore, the researchers identified a genetic variation linked to significantly higher blood levels of ImP, present in roughly 43% of the study participants. This genetic variant is suspected to affect how efficiently the kidneys clear the molecule from the body.
A New Therapeutic Target
Targeting ImP could eventually lead to preventive therapies, similar to how statins lower cholesterol to reduce heart disease risks. However, dietary restrictions alone are insufficient, as the molecule is produced when gut bacteria process histidine, an essential amino acid found abundantly in protein-rich foods.
"Improving your overall diet will probably help, but it's not as simple as saying 'stop eating eggs' or 'don't eat so much red meat' because you need histidine, and it's everywhere," noted Professor Barbara Bendlin. Instead, scientists hope to develop targeted inhibitors to safely reduce blood ImP levels.
